Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Bridget Silverman
Novartis’ Attention To Tropical Diseases Pays Off: Liver Fluke Drug Egaten Earns Priority Review Voucher
The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.